Alzheimer’s Gene Therapy: siRNA & Nanotech by Global Team
HKMU Scholar Co-Leads an International Study on a New Drug for Alzheimer's Disease Using Nanotechnology and Gene Therapy
Tags: Hong Kong Metropolitan University, Hong Kong, Healthcare & Lifesciences
A Hong Kong-led team, including researchers from City University of Hong Kong, The University of Hong Kong, University of Cambridge, Imperial College London, University College London, National University of Singapore, and Queen Mary Hospital, has developed a potential Alzheimer’s drug combining nanotechnology and gene therapy to inhibit harmful protein production in the brain. The drug uses small interfering RNA (siRNA) delivered via lipid nanoparticles, allowing it to penetrate the blood-brain barrier and target genes linked to Alzheimer’s. This approach aims to reduce beta-amyloid protein formation, a key cause of neuronal damage in Alzheimer’s patients. Applications include early therapeutic intervention for those at risk of cognitive decline and symptom relief for advanced cases. The team’s rigorous pre-clinical research and bioinformatics-backed siRNA design offer hope for Alzheimer’s management.
IP Type or Form Factor: Material; Process & Method
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Biotechnology; Mental Health
